Cholerose

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cholerose

What is Cholerose?

Cholerose is a pharmaceutical medication classified as a statin, a group of drugs primarily used to manage and improve lipid profiles in individuals with various forms of cholesterol imbalances. It belongs to the class of HMG-CoA reductase inhibitors, which are designed to address the underlying mechanisms of cholesterol production within the body.

Mechanism of Action

The active component in Cholerose works by inhibiting the enzyme HMG-CoA reductase, which plays a critical role in the liver's production of cholesterol. By reducing the internal synthesis of cholesterol, the medication helps lower the levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol, and triglycerides in the bloodstream. Additionally, it can contribute to a modest increase in high-density lipoprotein (HDL) cholesterol, commonly known as "good" cholesterol.

Clinical Applications

Cholerose is utilized in clinical settings for several purposes related to cardiovascular health:

  • Hyperlipidemia Management: It is used to treat primary hypercholesterolemia or mixed dyslipidemia when dietary changes and exercise alone are insufficient.
  • Cardiovascular Risk Reduction: In individuals with established cardiovascular disease or those at high risk due to factors such as diabetes or hypertension, the medication is used to reduce the likelihood of cardiovascular events like heart attacks or strokes.
  • Slowing Atherosclerosis: By managing lipid levels, Cholerose helps slow the progression of plaque buildup in the arterial walls, a process known as atherosclerosis.

Therapeutic Context

Cholerose is intended to be used as a supplement to a heart-healthy lifestyle. This typically includes a diet low in saturated fats and cholesterol, regular physical activity, and weight management. The goal of treatment is to reach specific lipid targets determined by a healthcare professional based on an individual's overall health profile and risk factors.

Regulatory References

  1. Rosuvastatin Drug Information

What side effects are possible with Cholerose?

Possible Side Effects and Safety Information

Adverse reactions to Rosuvastatin (Cholerose) are officially categorized by frequency and the body system affected, according to regulatory documents. Reactions classified as Common include general effects such as headache, dizziness, constipation, nausea, abdominal pain, and myalgia (muscle pain). The development of diabetes mellitus is also listed as a common reaction in some labels, particularly in patients with pre-existing risk factors.

The safety profile involves several System-Organ Classes (SOCs). Musculoskeletal Disorders are a primary concern, involving the rare, but serious, documented risks of myopathy and rhabdomyolysis. Hepatobiliary Disorders include rare reports of severe reactions such as hepatitis and jaundice. These serious events are generally rare but are explicitly highlighted in the official regulatory documentation.

Safety statements identify specific populations and conditions where caution is required. Patients of Asian descent may experience increased systemic exposure, and a lower maximum dose is specified for individuals with severe renal impairment. The risk of severe muscle effects is often tied to the highest dose ( 40 mg) and to co-administration with certain medications, such as Cyclosporine. Rosuvastatin is generally contraindicated in individuals with active liver disease or unexplained, persistent elevations of serum transaminases, establishing clear safety boundaries for its use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for the active ingredient, Rosuvastatin, establishes the actions required following a suspected overdose, emphasizing immediate medical intervention and structured monitoring. Experience with acute Rosuvastatin overdose in humans is limited, and no specific clinical signs or symptoms are consistently documented as being associated with the event itself.

Required Emergency Actions and Monitoring

If an overdose is suspected, individuals must seek immediate medical attention by contacting a doctor, emergency services, or a poison control center right away. Treatment for Rosuvastatin overdose is officially defined as symptomatic and supportive.

Monitoring Requirements Antidote Status
Monitoring of creatine kinase (CK) levels is required. No specific antidote is known for Rosuvastatin overdose.
Monitoring of Liver Function Tests (LFTs) is required. Hemodialysis is not anticipated to be of benefit due to high plasma protein binding.

These mandated monitoring parameters address the documented risk of musculoskeletal and hepatic toxicity, which are primary concerns in high-exposure scenarios, particularly in patients with severe renal impairment. The focus on supportive care and laboratory assessment dictates the entire regulatory approach to overdose management.

Therapeutic Uses of Cholerose

What Cholerose Treats: Main Uses and Benefits

Cholerose is primarily used to address conditions characterized by elevated levels of LDL cholesterol and triglycerides in the blood. By supporting the reduction of these lipids, the medication aims to reduce the overall cardiovascular risk profile. This includes situations like primary hypercholesterolemia and mixed dyslipidemia, particularly when dietary adjustments alone have not been sufficient.

The drug is also utilized for secondary prevention in patients who have established atherosclerotic cardiovascular disease (ASCVD). In these clinical scenarios, Cholerose contributes to lowering the progression of plaque build-up in the arteries. These therapeutic applications focus on the long-term management of cardiovascular health markers.

Furthermore, Cholerose is utilized as an additional therapy for individuals diagnosed with Familial Hypercholesterolemia (FH). This genetic disorder may benefit from robust lipid management, and the drug may help support the stabilization of lipid markers. The consistent use of Cholerose may support improvements in general well-being as part of a comprehensive management plan.

Quick Fact: Relief for Elevated Lipids

Eligibility and Restrictions for Use

Cholerose (rosuvastatin/ezetimibe combination) eligibility is strictly defined by regulatory bodies based on documented contraindications and specific patient factors. It is indicated for use primarily in adult patients (typically 18 years) and is generally not established for the pediatric population.

Absolute Contraindications

Condition / Population Status
Active liver disease, including unexplained liver enzyme elevation (3 x ULN) Contraindicated
Pregnancy, Lactation, or Women of childbearing potential not using contraception Contraindicated
Hypersensitivity to rosuvastatin, ezetimibe, or any excipients Contraindicated

Restricted or Conditional Use

Patients with severe renal impairment (Creatinine Clearance <30 mL/min) must not be given the highest doses, and use with caution is required. The 40 mg rosuvastatin dose is often contraindicated in those with moderate renal impairment or predisposing factors for myopathy, such as uncontrolled hypothyroidism, personal history of muscle disorders, or age over 70 years. Caution is also advised, and a lower starting dose is often recommended, for patients of Asian ancestry due to documented differences in drug exposure.

What should I know about interactions with other medicines?

Cholerose interacts with several medicines, patterns which are exclusively documented in official regulatory prescribing information. The official drug label information classifies these interactions based on their mechanism and resulting clinical restrictions.


Interaction-Related Restrictions and Contraindications

The most critical interaction involves Cyclosporine, which is classified as a contraindicated combination by some authorities due to its potent effect on drug transporters. Further restrictions mandate strict maximum daily dose limits when Cholerose is co-administered with specific inhibitors, including Darolutamide and Gemfibrozil. Co-administration with select Hepatitis C antiviral combinations (e.g., Sofosbuvir/Velpatasvir/Voxilaprevir) is formally not recommended due to the risk of increased exposure.

Documented Interaction Mechanisms

The principal interaction mechanism is pharmacokinetic, driven by the inhibition of drug uptake and efflux transporters, specifically OATP1B1 and BCRP. This inhibition causes a clinically significant increase in Cholerose's systemic exposure. Separately, co-administration with agents like Fibrates or high-dose Niacin (≥1 g/day) results in a pharmacodynamic interaction, officially stating an increased risk of skeletal muscle effects. The use of Coumarin Anticoagulants may also prolong the International Normalized Ratio (INR).

Timing and Population-Specific Rules

Official labeling mandates a timing-based interaction rule: Aluminum and Magnesium Hydroxide Antacids must be taken at least two hours after Cholerose to prevent reduced absorption. Furthermore, specific precautions are documented for the Asian patient population due to observed higher drug exposure, which may necessitate a lower starting dose.

Mechanism of Action

Cholerose (Rosuvastatin) primarily acts within the liver as a selective competitive inhibitor of the enzyme HMG-CoA reductase. This enzyme catalyzes the rate-limiting step in the mevalonate pathway, directly limiting the hepatocyte's capacity for endogenous cholesterol synthesis. This molecular blockade reduces the liver's internal cholesterol concentration, initiating a cellular response.

In response to the lowered intracellular cholesterol pool, the hepatocyte surface increases its expression of LDL Receptors. This receptor upregulation accelerates the hepatic catabolism (removal) of circulating Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream, resulting in a substantial reduction in plasma LDL-C concentrations.

Secondary to the primary action, the inhibition of the mevalonate pathway reduces the synthesis of isoprenoid intermediates. This modulation contributes to pleiotropic effects by influencing the activation of cell-signaling proteins (like Rho/Rac GTPases), which influence signal transduction pathways relevant to endothelial stability and modulate local inflammatory signaling.

Dosage and Administration Information

Administration Protocol for Cholerose

Cholerose (Rosuvastatin) is formulated as an oral film-coated tablet and is administered as a single dose once daily, with or without food, at any time of day.

Dosing and Administration Protocol

The standard adult dosage range is 5 mg to 40 mg once daily. Treatment is typically initiated at a starting dose of 10 mg or 20 mg. The dose can be adjusted, or titrated, at intervals of four weeks or more following the start of therapy or a previous dose change. The maximum dose of 40 mg is reserved only for patients who have not achieved their specific therapeutic lipid goals utilizing the 20 mg dose.

Special Patient Population Rules

Standard administration includes specific rules for certain groups. For patients of Asian ancestry, a starting dose of 5 mg is considered due to potential increases in systemic exposure. In cases of severe renal impairment (non-hemodialysis patients), the starting dose is 5 mg once daily and the total dose must not exceed 10 mg once daily. Additionally, for patients over 70 years of age, a 5 mg starting dose is generally recommended.

Procedural Constraints

To ensure proper use, the tablet must be swallowed whole and should not be crushed, dissolved, or chewed. If a dose is missed, the standard procedure is not to take an extra dose to compensate but to continue with the next scheduled daily dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cholerose

Evidence for Managing High Cholesterol and Mixed Lipids

Research explored the use of Cholerose (Rosuvastatin) primarily in Randomized Controlled Trials (RCTs) applied in adults with elevated cholesterol. Researchers monitored key biomarkers, such as Low-Density Lipoprotein Cholesterol (LDL-C), to observe how they changed over defined time intervals. Studies report how these markers evolved in the observed populations, with research describing patterns of change in LDL-C over the short-to-intermediate term. However, evidence concerning long-term clinical events is not fully established by these specific short-duration studies.

Evidence for Primary Prevention of Cardiovascular Events

To assess patterns related to preventing a first heart attack or stroke, large-scale, long-duration RCTs were used. These were applied in high-risk, but otherwise healthy adults. Studies monitored major clinical endpoints (MACE), such as cardiovascular death and nonfatal stroke. Research describes patterns related to the incidence of these events observed in the evaluated population. The results apply only to the specific populations studied, and some trials had follow-up durations that were limited.

Evidence Related to Arterial Plaque Progression

Research examined the medicine's use in individuals with subclinical atherosclerosis through controlled trials that primarily utilized imaging technology. Researchers measured the annual rate of change in Carotid Intima-Media Thickness (CIMT), an assessment used to track structural changes in artery walls. Since CIMT is a surrogate measure (an indirect marker), the research does not determine whether the anatomical changes observed directly lead to a change in long-term clinical outcomes. This relationship is one area where certainty remains low.

Evidence in Specialized and High-Risk Populations

Cholerose was studied for individuals with Familial Hypercholesterolemia (FH), including both adults and pediatric patients (children and adolescents). These trials were smaller and monitored measurements related to changes in LDL-C for both subgroups. Due to the rarity of the conditions studied, sample sizes were modest, and the evidence is limited for long-term clinical outcomes in these specialized groups. Data for certain groups remain insufficient, particularly concerning long-term durability.

Understanding Research Gaps and Uncertainty

The research evidence contributes to the broader evidence landscape by providing data on both immediate biomarker response and sustained clinical patterns. However, long-term effects are not fully established beyond the observation period of the major prevention studies. Research does not currently provide comprehensive, standardized data on the long-term durability for maintenance.

Frequently Asked Questions (FAQ)

Common questions about Cholerose (FAQ)


Q: Does Cholerose contain sulfa or penicillin?

Official documents containing the full list of ingredients (excipients) for Cholerose detail the active substance, Rosuvastatin calcium, and other compounds. While regulatory information doesn't explicitly state the absence of every possible allergen, the complete inactive ingredient list is available for review for specific allergen concerns.


Q: How quickly does Cholerose start to work?

According to official pharmacokinetic data, the active ingredient in Cholerose reaches its highest concentration in the bloodstream (peak plasma concentration) about 3 to 5 hours after a dose is taken. This information describes the observed pattern of absorption of the medication in the body.


Q: How long does the effect of Cholerose last after taking a dose?

The official product information indicates the elimination half-life of the active ingredient is approximately 19 hours. The half-life refers to the time it takes for half of the drug to be removed from the bloodstream. This duration is consistent with the drug’s designation as a once-daily formulation.


Q: Can Cholerose cause weight gain or loss?

Weight changes are not listed as common side effects in the official labeling for Cholerose. However, some patients who experience other reported side effects, such as muscle pain or changes in activity, may note fluctuations in their weight.


Q: Are there any foods or drinks to avoid while using Cholerose?

Official product labeling advises patients to limit or avoid substantial quantities of alcohol due to a potential increase in the risk of liver problems. Additionally, if using aluminum and magnesium hydroxide antacids, official guidance states they must be taken at least two hours after Cholerose to prevent reduced absorption of the medication.


Q: Is Cholerose safe to use with over-the-counter pain relievers like Advil or Tylenol?

The official drug label does not specifically detail interactions with common over-the-counter pain relievers such as ibuprofen or acetaminophen. Patients are generally advised to provide their prescriber with a complete list of all medications and supplements taken, including any non-prescription products.


Q: What happens if I take Cholerose with grapefruit juice?

Unlike some other drugs in this class, the official rosuvastatin label does not list grapefruit or grapefruit juice as a specific interaction or contraindication. Patients typically discuss any significant dietary changes, such as the regular consumption of grapefruit juice, with their healthcare provider.


Q: Is a metallic taste in the mouth a side effect of Cholerose?

A metallic taste is not commonly reported or listed among the frequent side effects documented in the official regulatory product information. The common side effects typically reported include headache, dizziness, constipation, nausea, abdominal pain, and muscle pain.


Q: Can Cholerose cause hair loss?

Official postmarketing surveillance reports have included alopecia (hair loss) as a rare event observed with this drug class. This information is noted in regulatory documents, although it is not considered a common reaction.


Q: Why does the packaging say to avoid alcohol while taking Cholerose?

Official warnings regarding Cholerose and alcohol consumption relate to the potential for liver damage. Because the medication is processed by the liver, consuming substantial amounts of alcohol may increase the overall risk of liver enzyme elevations and hepatotoxicity.


Q: Where can I find the official prescribing information for Cholerose?

The complete and official prescribing information for Cholerose (Rosuvastatin) can be accessed on government websites, such as those run by the U.S. Food and Drug Administration (FDA) or the National Institutes of Health (NIH) DailyMed.


Q: Is Cholerose a generic drug or a brand name?

The active ingredient, Rosuvastatin, is available in both brand-name and generic formulations following the drug’s patent expiration. Cholerose is the product name. The active ingredient, Rosuvastatin, is available as both a brand-name and generic product.


Q: Does Cholerose interact with birth control pills?

Yes, official drug interaction information states that coadministration with oral contraceptives can increase the concentration of certain hormones in the blood, specifically ethinyl estradiol and norgestrel. Regulatory information advises that healthcare providers be informed if a patient is using oral contraception.


Q: Can I take Cholerose if I have a history of heart issues?

Official contraindications are focused on conditions like active liver disease, pregnancy, and hypersensitivity. The drug is indicated for use in certain populations with high cardiovascular risk factors, including those with elevated lipids.


Q: What happens if I stop taking Cholerose suddenly?

Stopping Cholerose suddenly will not cause withdrawal symptoms since it is not a physically addictive medication. However, official guidance indicates that discontinuing treatment may cause an increase in your cholesterol levels, returning them toward pre-treatment levels.


Q: Can Cholerose be taken by people who are lactose intolerant?

Official composition information for the tablet formulation of Cholerose notes that it contains lactose monohydrate as an inactive ingredient (excipient). Patients with known lactose intolerance typically discuss the use of this formulation with their healthcare provider.


Q: Why is my doctor asking me to get lab work done while on Cholerose?

Regulatory guidelines recommend blood tests for monitoring due to potential serious, though rare, effects on the liver and muscle. Liver enzyme tests are often performed before and during therapy to check for liver enzyme abnormalities. Monitoring may also be used to check for severe muscle effects.


Q: What does 'contraindication' mean in the context of Cholerose?

A contraindication is a factor or condition that legally and clinically requires a medical treatment to be withheld because the risks of harm significantly outweigh any potential benefit. For Cholerose, official contraindications include active liver disease and pregnancy.


Q: What is the purpose of the boxed warning, if any, on Cholerose?

Cholerose (rosuvastatin) does not currently have a Black Box Warning (the FDA’s strongest warning). However, the label contains significant warnings about serious risks, including myopathy (muscle disease) and liver enzyme abnormalities.


Q: Can Cholerose be used for conditions other than the one it is approved for?

The official product label specifies a set of approved indications and usages, which include lowering elevated cholesterol and triglyceride levels, and preventing major cardiovascular events in certain groups. The drug is intended to be used as specified in these official indications.


Q: What is the half-life of Cholerose?

According to official pharmacokinetic data, the elimination half-life of the active ingredient in Cholerose is approximately 19 hours.


Q: What are the common signs of an allergic reaction to Cholerose?

Official regulatory documents list signs of a serious hypersensitivity reaction which may include difficulty breathing, swelling of the face, lips, tongue, or throat, hives, or rash.


Q: Can Cholerose affect mood or cause anxiety?

Official postmarketing reports have noted psychiatric effects in the drug class, such as confusion, depression, and insomnia (difficulty sleeping). Mood disorders or anxiety are not commonly listed as frequent side effects, but changes in mood or anxiety are factors that are typically reported to a healthcare provider.


Q: Is Cholerose a controlled substance?

Cholerose (rosuvastatin) is a prescription-only medication, but it is not classified as a controlled substance by regulatory authorities such as the U.S. Drug Enforcement Administration (DEA).

How should Cholerose be stored and disposed of?

How to Store and Dispose of Cholerose?

The storage of Cholerose (rosuvastatin calcium) tablets is officially mandated to ensure product stability. The medication must be kept at Controlled Room Temperature, typically 20 C to 25 C, with excursions only permitted between 15 C and 30 C.

Environmental Protection

The tablets must be protected from moisture and stored in the original container to shield them from light and freezing temperatures. Keeping the container tightly closed helps preserve product integrity.

Safety and Disposal

Cholerose must always be stored out of the sight and reach of children. Unused or expired medicine should be disposed of according to local regulations. This typically involves utilizing a drug take-back program or following official guidance for household disposal to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cholerose found in:

A-Z Index: